维拉帕米普通剂型的血浆半衰期仅4小时,必须每日口服3～4次。本试验表明,慢性稳定型心绞痛患者每日一次口服维拉帕米缓释剂型(VSR)360mg,血浆药物浓度维持在治疗浓度(15～100ng/ml)之上长达24小时;使运动耐量提高,心绞痛发作次数和硝酸甘油用量趋于减少;患者耐受良好、副作用轻微。较大剂量VSR提高疗效仍待验证。平均年龄57.9(41～72)岁的19(男18、女1)例慢性稳定型心绞痛患者参加本试验。各例经造影证实 The verapamil common dosage form has a plasma half-life of only 4 hours and must be orally administered 3 to 4 times daily. This trial showed that 360 mg of verapamil sustained-release formulation (VSR) was administered orally once daily to patients with chronic stable angina and the plasma drug concentration was maintained at a therapeutic concentration of 15 to 100 ng / ml for up to 24 hours; increased exercise tolerance , The number of angina attacks and the amount of nitroglycerin tended to decrease; patients were well tolerated with minor side effects. Larger doses of VSR to improve efficacy remains to be verified. A total of 19 (18 male and 1 female) chronic stable angina patients aged 57.9 years (41-72 years) participated in this study. Each case confirmed by radiography